Analysts Expect Abeona Therapeutics Inc (NASDAQ:ABEO) to Announce -$0.05 Earnings Per Share

Analysts forecast that Abeona Therapeutics Inc (NASDAQ:ABEOGet Rating) will report ($0.05) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Abeona Therapeutics’ earnings. Abeona Therapeutics reported earnings per share of ($0.16) during the same quarter last year, which suggests a positive year-over-year growth rate of 68.8%. The firm is scheduled to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Abeona Therapeutics will report full year earnings of ($0.31) per share for the current financial year, with EPS estimates ranging from ($0.43) to ($0.18). For the next financial year, analysts forecast that the firm will post earnings of ($0.13) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEOGet Rating) last released its quarterly earnings results on Friday, May 13th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04).

Several brokerages have recently issued reports on ABEO. Zacks Investment Research raised Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $0.25 target price for the company in a research report on Monday. StockNews.com began coverage on Abeona Therapeutics in a research report on Sunday, May 29th. They set a “hold” rating for the company. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $1.75.

Hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP bought a new position in shares of Abeona Therapeutics during the 3rd quarter worth $37,000. Citigroup Inc. bought a new position in shares of Abeona Therapeutics during the 1st quarter worth $27,000. Acadian Asset Management LLC bought a new position in shares of Abeona Therapeutics during the 4th quarter worth $78,000. Virtu Financial LLC bought a new position in Abeona Therapeutics in the 4th quarter worth about $84,000. Finally, ACT Capital L.L.C. bought a new position in Abeona Therapeutics in the 3rd quarter worth about $311,000. Institutional investors own 27.81% of the company’s stock.

Shares of Abeona Therapeutics stock opened at $0.16 on Friday. Abeona Therapeutics has a 1 year low of $0.13 and a 1 year high of $1.92. The firm has a market cap of $22.78 million, a PE ratio of -0.19 and a beta of 1.51. The stock has a fifty day moving average price of $0.22 and a 200-day moving average price of $0.32.

About Abeona Therapeutics (Get Rating)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Featured Articles

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Want More Great Investing Ideas?

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.